Literature DB >> 2802277

Treatment of uncontrolled hemorrhagic shock by hypertonic saline and external counterpressure.

E H Landau1, D Gross, A Assalia, M M Krausz.   

Abstract

The effect of an external counterpressure device (ECPD) on hypertonic saline treatment of uncontrolled hemorrhagic shock (UCHS) was studied in rats. The rats were divided into five groups. In group 1 (n = 11) UCHS induced by incision of three radicals of the ileocolic artery was treated by 5 mL/kg NaCl 0.9% (normal saline). In group 2 (n = 20), UCHS was treated by 5 mL/kg NaCl 7.5% (hypertonic saline). In group 3 (n = 6), UCHS was treated by inflation of ECPD to 50 torr. In group 4 (n = 7), UCHS was treated by ECPD and normal saline; in group 5 (n = 9), UCHS was treated by ECPD and hypertonic saline. Incision of the ileocolic artery in group 1 rats led to a fall in mean arterial pressure to 33 torr (P less than .001) followed by a spontaneous rise to 48 torr (P less than .01) with a mortality rate of 27% and a mean survival time of 161 +/- 9 minutes. Infusion of hypertonic saline during UCHS was followed by a further fall in mean arterial pressure to 18.5 torr (P less than .001); mortality was 80% within 80 minutes with a mean survival time of 35.5 minutes, which was significantly lower than in group 1 (P less than .01). Inflation of ECPD during UCHS in group 3 or treatment with ECPD and normal saline in group 4 did not alter the hemodynamic response and mortality, which were similar to those of group 1.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2802277     DOI: 10.1016/s0196-0644(89)80926-6

Source DB:  PubMed          Journal:  Ann Emerg Med        ISSN: 0196-0644            Impact factor:   5.721


  1 in total

1.  Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension. The U.S.A. Multicenter Trial.

Authors:  K L Mattox; P A Maningas; E E Moore; J R Mateer; J A Marx; C Aprahamian; J M Burch; P E Pepe
Journal:  Ann Surg       Date:  1991-05       Impact factor: 12.969

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.